







































Identifying Thoracic Malignancies Through Pleural
Fluid Biomarkers
A Predictive Multivariate Model
José M. Porcel, MD, Aureli Esquerda, PharmD, Montserrat Martı́nez-Alonso, PhD,
Silvia Bielsa, MD, and Antonieta Salud, MD
Abstract: The diagnosis of malignant pleural effusions may be
challenging when cytological examination of aspirated pleural fluid
is equivocal or noncontributory. The purpose of this study was to
identify protein candidate biomarkers differentially expressed in the
pleural fluid of patients with mesothelioma, lung adenocarcinoma,
lymphoma, and tuberculosis (TB).
A multiplex protein biochip comprising 120 biomarkers was used to
determine the pleural fluid protein profile of 29 mesotheliomas, 29 lung
adenocarcinomas, 12 lymphomas, and 35 tuberculosis. The relative
abundance of these predetermined biomarkers among groups served to
establish the differential diagnosis of: malignant versus benign (TB)
effusions, lung adenocarcinoma versus mesothelioma, and lymphoma
versus TB. The selected putative markers were validated using widely
available commercial techniques in an independent sample of 102
patients.
Significant differences were found in the protein expressions of
metalloproteinase-9 (MMP-9), cathepsin-B, C-reactive protein, and
chondroitin sulfate between malignant and TB effusions. When inte-
grated into a scoring model, these proteins yielded 85% sensitivity,
100% specificity, and an area under the curve (AUC) of 0.98 for labeling
malignancy in the verification sample. For lung adenocarcinoma–
mesothelioma discrimination, combining CA19-9, CA15-3, and kallik-
rein-12 had maximal discriminatory capacity (65% sensitivity, 100%
specificity, AUC 0.94); figures which also refer to the validation set.
Last, cathepsin-B in isolation was only moderately useful (sensitivity
89%, specificity 62%, AUC 0.75) in separating lymphomatous and TB
effusions. However, this last differentiation improved significantly
when cathepsin-B was used with respect to the patient’s age (sensitivity
72%, specificity 100%, AUC 0.94).
In conclusion, panels of 4 (i.e., MMP-9, cathepsin-B, C-reactive
protein, chondroitin sulfate), or 3 (i.e., CA19-9, CA15-3, kallikrein-12)
different protein biomarkers on pleural fluid samples are highly dis-
criminative for signaling a malignant versus tuberculous effusion, or
lung adenocarcinoma versus mesothelioma, respectively. Cathepsin-B
could also be helpful in establishing the presence of a lymphomatous
effusion versus that of TB, if the patient’s age is simultaneously taken
into consideration.
(Medicine 95(10):e3044)
Abbreviations: ADA = adenosine deaminase, AUC = area under
the curve, FDR = false discovery rate, MMP = metalloproteinase,
TB = tuberculosis.
INTRODUCTION
M alignant pleural effusions are most quickly and easilydiagnosed through a pleural fluid cytological examin-
ation. However, the cytological yield depends on many factors
and is reported to be a maximum of 60%, although it is much
lower in mesothelioma and squamous cell lung cancer.1 There-
fore, the search for pleural fluid biomarkers of malignancy with
the aim of avoiding further unnecessary invasive procedures or
selecting those patients who may benefit the most from them is
an ongoing quest.
To discriminate between malignant and tuberculous (TB)
effusions may be difficult. First, because the biochemical
characteristics of both malignant and TB pleural fluids are
similar in that they are usually lymphocytic exudates. And
second, pleural fluid adenosine deaminase (ADA), which is
>35 to 40 U/L in 92% of TB effusions, has been reported to be
falsely elevated in 10% of malignancies in general, and nearly
60% of lymphomas in particular.2 Thus, separating TB and
lymphomatous effusions may pose a particular challenge and
often requires immunophenotyping of lymphocytes into B- and
T-cell subgroups (a predominance of small T-cells usually
represents a benign process such as TB). Also demanding
attention is the fact that when malignant cells are observed
in pleural fluid, immunocytochemical studies of varying com-
plexity are often necessary to distinguish between adenocarci-
noma and mesothelioma.3 The underlying reason is that
overlapping cytomorphological features of adenocarcinoma,
reactive mesothelial cells, and malignant mesothelioma exist.
According to the preceding text, 3 potentially challenging
scenarios could be envisioned in clinical practice, namely the
differentiation of malignant and TB effusions, lung adenocar-
cinomas from mesotheliomas, and lymphomas with falsely
elevated ADA from TB. In this study, we took advantage of
protein microarray technologies applied to pleural fluid speci-
mens for accomplishing these tasks. Initially, we searched for
the most accurate protein combinations from a commercially
available microarray biochip comprising 120 different proteins.
Then, the results were validated in an independent population
by using more clinically accepted protein methodologies.
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SUBJECTS AND METHODS
Study Population
We have been maintaining a pleural fluid database and
biobank of fluid specimens from every patient subjected to a
diagnostic thoracentesis at the Arnau de Vilanova University
Hospital (Lleida, Spain) for the last 18 years. All tapped pleural
fluids are collected into EDTA tubes, centrifuged at 48C, and
the supernatant is frozen and stored at808C until assayed. For
the current investigation, we used a computer-generated stra-
tified randomization of effusions to initially select 78 samples,
collected from 2001 to 2011 in our hospital, with the following
etiological distribution: 30 lung adenocarcinomas, 12 lympho-
mas with high pleural fluid ADA levels, and 36 TB. Due to the
low prevalence of mesotheliomas in the immediate local area,
30 such neoplasms originating from a different Spanish center
(Hospital Universitario Virgen del Rocı́o, Sevilla, Spain) were
incorporated into this derivation set. Each pair of independent
samples of mesothelioma, lung adenocarcinoma, lymphoma,
and TB was age- and sex-matched for comparisons. An inde-
pendent randomly selected population of 30 lung adenocarci-
nomas, 20 mesotheliomas, 34 TB, and 18 lymphomas from our
biobank served to validate the results of the protein microarrays
applied to the derivation set. All pleural fluids which were
analyzed had been collected before the institution of any
specific treatment, including either antituberculous drugs or
chemotherapy. The study was performed following the TRI-
POD (transparent reporting of a multivariate prediction model
for individual prognosis or diagnosis) statement.4 Approval for
the study was obtained from the local ethics committee (CEIC,
Arnau de Vilanova University Hospital, ID 764).
Diagnostic Criteria for Pleural Effusions
The diagnosis of malignant effusions, whether mesothe-
liomas, adenocarcinomas, or lymphomas, was based on the
demonstration of malignant cells in pleural fluid or biopsy
specimens by an experienced pathologist. Specifically, an
adequate tissue biopsy sample with the use of appropriate
immunohistochemistry panels (i.e., at least 2 positive mesothe-
lial markers and 2 negative adenocarcinoma markers) was
required for confirming the diagnosis of mesothelioma.3 Com-
monly used immunohistochemical stains included mesothelin,
cytokeratin 5/6, Wilms tumor-1 (mesothelioma markers); cal-
retinin (mesothelial cell marker); epithelial membrane antigen
(marker of malignancy, either mesothelioma, or adenocarci-
noma); desmin (marker of reactive mesothelium); and thyroid
transcription factor-1, napsin A and carcinoembryonic antigen
(markers of adenocarcinoma). Additional stainings were per-
formed in equivocal cases. TB pleuritis was diagnosed if Low-
enstein–Jensen cultures of pleural fluid, sputum or pleural
biopsy tissue samples were positive, or parietal pleural biopsies
showed granulomas (i.e., confirmed TB cases), or an exudative
lymphocytic effusion with high ADA levels (>35 U/L) cleared
in response to anti-TB therapy in the absence of any other
obvious explanation for the pleural fluid accumulation (i.e.,
probable TB cases).
Microarray Protein Analyses
Pleural fluid samples from the derivation set were tested
with the Whatman Schleicher & Schuell serum biomarker chip
(Whatman GmbH, Dassel, Germany), according to the manu-
facturer’s instructions. In brief, the chip consists of a single
antibody capture array built on the FAST Slide dual pad
platform. Each slide has 2 identical arrays of 120 antibodies
printed in triplicate, which represent a myriad of biomarkers
associated with human cancer. The original antibody chip was
modified by replacing the free form of the prostate-specific
antigen with mesothelin (Table 1). A pleural fluid volume of 1.5
to 6 mL was used to achieve a total protein amount of 100 to
120 mg in the slide chambers for incubation and labeling
reaction. Two-color fluorescent detection (Biotin-ULS and
Fluorescein-ULS) enabled spot intensity mapping of the
relative abundance of the 120 proteins between 2-paired
samples, one from the malignant disease (cases) and the other
from TB (controls). Spot intensities were displayed using
ArrayVision FAST software, and a bioinformatic analysis
converted fluorescent data into numerical values which
represented the abundance of antigen in cases relative to con-
trols. The ratio of the average spot intensities for each paired
samples was plotted on a Log 2 scale to reveal the over- and
under-abundance pleural fluid biomarkers in cancer patients as
compared to TB or, where appropriate, in lung adenocarcinoma
versus mesothelioma. The first step of sample labeling with
Biotin and Fluorescein was performed in our center. Labeled
microarrays were then sent for both scanning (Axon GenePix
4200A, Molecular Devices Corporation, Sunnycale, CA) and
data analysis in blinded fashion to the Maine Manufacturing
LLC company (Sanford, ME).
Other Pleural Fluid Measurements
Pleural fluid ADA levels were determined by using an
automated ultraviolet kinetic assay (Roche Diagnostics, Barce-
lona, Spain). Nine biomarkers, which were selected as poten-
tially discriminatory from the derivation sample, were
measured either by enzyme-linked immunosorbert assays
(human cathepsin-B, human kallikrein-12, human condroitin
sulfate, human matrix metalloproteinase 3 [MMP-3], human
matrix metalloproteinase 9 [MMP-9], and human angiostatin;
Cusabio Biothech), a particle-enhanced immunoturbidimetric
assay (C-reactive protein; Roche Diagnostics GmbH, Man-
nheim, Germany), or electro-chemiluminiscence immunoas-
says (CA15-3 and CA19-9; Roche Diagnostics GmbH,
Mannheim, Germany) in the pleural fluid of an independent
population.
Statistical Analysis
Sample size calculation for the derivation set was based on
a previously proposed method for bilateral contrasts, aiming
for a statistical power of at least 80% and a false discovery rate
of 5%.5
Comparative analyses of the pleural fluid protein profiles
of malignant (i.e., adenocarcinomas plus mesotheliomas) versus
TB effusions, lung adenocarcinomas versus mesotheliomas, and
lymphomas versus TB (both exhibiting high fluid ADA levels)
were carried out. The results of a Pearson correlation, which
measured the linear relationship of the protein profiles among
groups, were graphically displayed using a heatmap. Differ-
ences in protein expression between groups were analyzed by
the Wilcoxon test, controlling the false discovery rate (FDR) at
P< 0.05. Then, tree-based algorithms were generated using
supervised Random forests (i.e., an ensemble classifier using
many decision tree models) multivariate methodologies to
lessen potential biomarker candidate proteins,6 and Gini index7
as an impurity-based criterion for calculating a node. These
classification algorithms were built through recursive partition-
ing or conditional inference.
Porcel et al Medicine  Volume 95, Number 10, March 2016
2 | www.md-journal.com Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
The chosen protein biomarkers from the training set were
subsequently validated for the 3 comparisons, using the like-
lihood ratio (LR) test to compare the goodness of fit between 2
models. First, logistic regression models were fitted and ROC
curves were used to calculate optimal cutoff values for indi-
vidual markers while searching for, whenever possible, a 100%
specificity. Then, a scoring system was devised in which weight
values to each biomarker were assigned proportionally to the
magnitude of the logistic equation’s coefficients. Finally, the
discriminative properties of the scoring model (i.e., sensitivity,
specificity, accuracy, LR positive, and negative) were esti-
mated. Whenever specificity was 100%, it was statistically
necessary to artificially add 1 case to the false positive cell
of a 2  2 table in order to enable the calculation of the LR
positive. The addition of sex and/or age to improve the dis-
crimination capability of protein-based scores was also
assessed. All analyses were performed with the R software
for statistical computing (http://www.r-project.org/).








Apolipoprotein A1 IgM Neuron-specific enolase
Apolipoprotein J IL-1a RANTES
Beta2 microglobulin IL-1b Osteopontin
Bone sialoprotein IL-2 PDGF (all isoforms)
CA15-3 IL-2 receptor-a PDGF (BB isoform only)
CA19-9 IL-2 receptor-b Placental alkaline phosphatase
CA50 IL-3 Plasminogen
CA125 IL-4 Plasminogen activator inhibitor
CEA (group 2 specific) IL-5 Prostatic acid phosphatase
CEA (group 4 specific) IL-6 PSA (total)
Cathepsin-B IL-7 PSA–ACT complex
Ceruloplasmin IL-8 S-100
Chondroitin sulfate IL-10 Sialyl Lewis X
Chorionic gonadotropin-a IL-12p40 TAG-72
Chorionic gonadotropin-b IL-12p70 Tetranectin
Chromogranin IL-13 TGF-a
Collagen type I IL-17 TGF-b
Complement C4 Insulin Thrombospondin-1
C-reactive protein Insulin-like growth factor 1 Thrombopoietin
Cyclin-dependent kinase inhibitor 2A Insulin growth factor binding protein 3 Thyroglobulin
CYFRA 21-1 Interferon-g TIMP-1
Eotaxin IP-10 TIMP-2
Epidermal growth factor Kallikrein-5 TNF-a
EGFR Kallikrein-9 TNF-b
ErbB2 Kallikrein-12 Transferrin
E-selectin Kallikrein-14 Tumor-associated trypsin inhibitor
Estrogen receptor Laminin Tyrosinase
Fas Low-density lipoprotein Urokinase plasminogen activator
Fas ligand MCP-1 VCAM-1
Ferritin MCP-2 VE-cadherin
Fibroblast growth factor-7 MCP-3 VEGF
Fibroblast growth factor-basic MCP-4 VEGF-D
G-CSF M-CSF Von Willebrand factor
CEA¼ carcinoembryonic antigen, EGFR¼ epidermal growth factor receptor, G-CSF¼ granulocyte colony-stimulating factor, GM-CSF¼
granulocyte-macrophage colony-stimulating factor, ICAM-1¼ intercellular adhesion molecule 1, Ig¼ immunoglobulin, IL¼ interleukin, IP-
10¼ interferon gamma-induced protein 10, MCP¼monocyte chemotactic protein, M-CSF¼macrophage colony-stimulating
factor, MIP¼macrophage inflammatory protein, MMP¼matrix metalloproteinase, PDGF¼ platelet-derived growth factor, PSA¼ prostate-
specific antigen, PSA-ACT¼ antichymotrypsin complexed-PSA, RANTES¼ regulated on activation, normal T-cell expressed and secreted,
TAG-72¼ tumor-associated glycoprotein 72, TGF¼ transforming growth factor, TIMP¼ tissue inhibitor of metalloproteinase, TNF¼ tumor
necrosis factor, VCAM-1¼ vascular cell adhesion molecule 1, VE-cadherin¼ vascular endothelial cadherin, VEGF¼ vascular endothelial
growth factor.
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RESULTS
Characteristics of the Study Population
Three cases (1 each mesothelioma, lung adenocarcinoma,
and tuberculosis) were excluded from the derivation analysis
because the biochip slides were accidentally broken during the
labeling procedure. Demographic and pleural fluid data of the
105 patients from the derivation sample and 102 patients from
the validation sample are presented in Table 2. Both groups
were homogeneous, though there were some minor statistical
differences in the baseline characteristics between them.
Specifically, the median age of the TB derivation sample
surpassed that of the validation sample (44 vs 31 years,
P<0.001), whereas less than one-third of lymphomatous effu-
sions from the validation population had high pleural fluid ADA
levels as compared to 100% of the derivation population. The
cause for this latter discrepancy was the difficulty in recruiting
new patients with such a relatively infrequent cause of
pleural effusion which, in addition, had to exhibit elevated
ADA concentrations.
Differential Protein Expression Between Groups
in the Derivation Sample
After graphically expressing protein correlations for the 3
groups of paired comparisons in a heat map matrix (Figure 1),
differentially expressed proteins were determined using the
FDR approach and random forest methodologies as a tree-based
method (Figure 2).
In the first comparison, proteins which most contributed to
discriminate between 58 malignant (of which half were lung
adenocarcinomas and half mesotheliomas) and their corre-
sponding paired TB effusions were MMP-9, cathepsin-B, C-
reactive protein, angiostatin, and chondroitin sulfate
(Figure 2A). A constructed tree with these respective proteins
running down the tree root, from the base to terminal nodes, had
a sensitivity of 95% (95% CI 86–99%), and a specificity of
84.7% (95% CI 73–92.8%) for labeling malignancy.
In the second comparison, a classification tree which
sequentially included the proteins CA19-9, CA15-3, MMP-3,
and kallikrein-12 (Figure 2B) yielded a sensitivity of 83% (95%
CI 64.2–94.2%) and a specificity of 89.7% (95% CI 73–98%)
for separating 29 lung adenocarcinomas from 29 mesothelio-
mas.
Finally, in the third, cathepsin-B (Figure 2C) was able to
discriminate 12 lymphomas with high ADA levels from 12 TB
with 100% sensitivity (95% CI 73.5–100%) and 83.3% speci-
ficity (95% CI 51.6–98%). This paper does not include a visual
depiction for any of these algorithms from the training set
because optimal cutoff points for each participating protein
were expressed as signal intensity units, which are of cumber-
some interpretation for the practicing physician.
Accuracy of Different Protein Profiles in the
Validation Sample
A different set of 20 malignant (10 lung adenocarcinomas,
5 mesotheliomas, and 5 lymphomas) and 20 TB effusions was
used to validate the usefulness of the previously selected
proteins in the microarray assays, but this time using commer-
cially available methodologies. We established a score system
as follows: MMP-9< 15.5 ng/mL (3 points), chondroitin sulfate
>1.25 ng/mL (3 points), cathepsin-B <0.42 ng/mL (2 points),
and C-reactive protein<12.5 mg/L (1 point). The model, which
excluded angiostatin as a significant contributor, had an area
under the curve (AUC) of 0.98 (95% CI 0.95–1) (Figure 3A). A
score 6 indicated malignancy with 85% sensitivity (95% CI
62.1–96.8%), 100% specificity (95% CI 83.2–100%), LR
positive of 17.9 (95% CI 2.6–121.9), and LR negative of
0.15 (95% CI 0.05–0.43) (Table 3).
Similarly, 20 lung adenocarcinomas and 20 mesotheliomas
were tested for the expression of the pleural fluid proteins
CA19-9, CA15-3, kallikrein-12, and MMP-3. The last was
dismissed by the following best scoring model, which had
an AUC of 0.94 (95% CI 0.88–1) (Figure 3B): CA19–9











Age, y 72 (64–77) 69.5 (61.5–75.5) 0.35
Male 24 (83%) 15 (75%) 0.72
Pleural fluid
protein, g/dL
4.4 (3.8–5) 4.2 (3.7–4.6) 0.41
ADA, U/L 25.7 (15.6–30) 22.3 (16.8–27.8) 0.91








Age, y 72 (64–76) 72.5 (60.3–80.8) 0.53
Male 24 (83%) 19 (63%) 0.14
Pleural fluid
protein, g/dL
4.5 (4.2–5.2) 4.4 (3.7–4.8) 0.24
ADA, U/L 23.3 (18.1–27.3) 18.3 (14.9–21.5) 0.0104
ADA >35 U/L 2 (7%) 0 (0%) 0.24
Lymphoma
No. 12 18
Age, y 58 (45.5–73.7) 72 (60.5–79.8) 0.25
Male 8 (67%) 8 (44%) 0.28
Pleural fluid
protein, g/dL
4.4 (3.9–4.5) 3.6 (3.3–4.5) 0.18
ADA, U/L 71.4 (43.5–159) 27.5 (17.4–36.5) < 0.001
ADA >35 U/L 12 (100%) 5 (28%) < 0.001
Tuberculosis
No. 35z 34z
Age, y 44 (38.5–53.5) 31 (26.3–38.8) < 0.001
Male 26 (74%) 22 (65%) 0.44
Pleural fluid
protein, g/dL
5.3 (4.8–5.7) 5.3 (4.8–5.7) 0.95
ADA, U/L 67.6 (60.2–82.7) 61.5 (52.6–75.3) 0.09
ADA >35 U/L 35 (100%) 33 (97%) 0.49
Data are expressed as No. (%), or median (quartiles) as appropriate.
Not all patients were used for the 3 comparisons (see the text).
yBy Fisher test and Mann–Whitney test for qualitative and quanti-
tative variables, respectively.
zThe diagnosis in 4 (11%) and 16 (47%) cases from the derivation
and validation groups, respectively, was based on a composite reference
standard (i.e., presenting signs and symptoms, pleural fluid biochem-
istries, including high ADA values, and response to antituberculous
therapy).ADA¼ adenosine deaminase.
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13.3 U/mL (3 points), kallikrein-12<55 ng/mL (2 points), and
CA15-3 >110 U/mL (1 point). A score 4 separated lung
adenocarcinomas from mesotheliomas with 65% sensitivity
(95% CI 40.8–84.6%), 100% specificity (95% CI 83.2–
100%), LR positive of 13.7 (95% CI 2–94.9), and LR negative
of 0.35 (95% CI 0.19–0.64) (Table 3).
Finally, a pleural fluid cathepsin-B level <0.31 ng/mL
yielded 89% sensitivity (95% CI 65.3–98.6%), 62% specificity
(95% CI 43.6–77.8%), LR positive of 2.3 (95% CI 1.5–3.7),
and LR negative of 0.18 (95% CI 0.05–0.68) for separating 18
lymphomas from 34 TB (Table 3). The AUC was 0.75 (95% CI
0.64–0.86) (Figure 3C). In the first 2 comparisons (malignant vs
TB, lung adenocarcinoma vs mesothelioma), the incorporation
of demographic data (age, sex) into the fluid biomarker panel
did not improve the operating characteristics of the scoring
models. However, this was not true for the discrimination of
lymphoma versus TB (see Table, supplemental content which
illustrates the corresponding LR tests, http://links.lww.com/
MD/A769). In particular, patients who scored 2 points, in which
1 point each was assigned to both pleural fluid cathepsin-B
concentrations <0.31 ng/mL and age 50 years, were most
likely to have lymphomas rather than TB (sensitivity 72.2%,
95% CI 46.5–90.3%; specificity 100%, 95% CI 89.7–100%;
LR positive 25.3, 95% CI 3.6–178.2; LR negative 0.28, 95% CI
0.13–0.59; and AUC 0.94, 95% CI 0.88–0.99).
The previous 3 scoring systems were obtained after dichot-
omizing the protein biomarker expressions, which showed
better discriminating properties than the use of continuous
protein expressions (see Figures 1–3, supplemental content
which illustrates calibration and ROC plots for both binary
and continuous approaches, http://links.lww.com/MD/A769).
DISCUSSION
In the current investigation, we used a protein chip array
technology to discover candidate pleural fluid biomarkers for
FIGURE 1. Heatmaps with linear correlations of proteins for the comparisons between malignant and TB effusions (A), lung adeno-
carcinoma versus mesothelioma (B), and lymphoma versus TB (C). Red corresponds to positive correlations (r¼1), green to negative
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FIGURE 2. Supervised random forest for the differentially expressed proteins among the 3 comparisons (A, malignant vs TB; B, lung
adenocarcinoma vs mesothelioma; C, lymphoma vs TB).TB¼ tuberculosis.
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malignancy. As the biomarker chip was simply a method to
ascertain protein abundance changes between biological
samples of different etiologies, we subsequently intended to
provide protein quantification by using commercially available
methodologies in an independent population.
First, it was found that the combined measurement in the
pleural fluid of MMP-9, chondroitin sulfate, cathepsin-B, and
C-reactive protein was highly accurate for discriminating
between malignant and benign (TB) effusions. When integrated
into a simple scoring system, these proteins yielded 85%
sensitivity and 100% specificity for labeling malignancy. Such
impressive figures contrast with the reported 60% sensitivity of
the cytological examination (the diagnostic gold standard)
while greatly surpassing that of classical tumor marker panels
(54% in a large single study in which maximal specificity was
attained).8 Except for chondroitin sulfate, the remaining 3
biomarkers were underexpressed in malignant fluids as com-
pared with TB. MMP-9 is involved in the development of TB
granulomas and, therefore, TB effusions contain higher con-
centrations when compared with malignant effusions and trans-
udates.9–11 Cathepsin-B belongs to a family of lysosomal
cysteine proteases and plays a role in intracellular proteolysis.
It is difficult to find a satisfactory explanation for why its
expression was downregulated in malignant effusions when
compared with TB. However, in some experimental models,
significant amounts of cathepsin-B were observed in washing
fluids of subcutaneous inflammatory foci of Mycobacterium
tuberculosis-induced hypersensitivity reactions.12 C-reactive
protein, an acute-phase protein widely used as a marker of
inflammation, may be a diagnostic aid in the differential
diagnosis of pleural effusions. Previous studies have consist-
ently reported that levels of C-reactive protein in pleural fluids
are 2 to 4 times higher in TB pleuritis than malignant effu-
sions;13–15 the more intense inflammation in the former as
compared with the latter probably accounts for this difference.
For example, in the largest study which comprised of 55 TB and
FIGURE 3. Receiver operating characteristic curves for the differentially expressed proteins among the 3 comparisons (A, malignant vs TB;
B, lung adenocarcinoma vs mesothelioma; C, lymphoma vs TB). TB¼ tuberculosis.
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60 malignant effusions, the mean pleural fluid C-reactive
protein levels were 54.6 mg/L and 12.6 mg/L respectively,13
which is consistent with our results. Finally, although chon-
droitin sulfate on the tumor cell surface and in the extracellular
matrixes is related to metastatic potential and facilitates tumor
invasion, it has never been tested before in pleural
fluid samples.
A second clinical challenge is the cytomorphological
differentiation between adenocarcinoma and mesothelioma.
In clinical practice, this discrimination requires the application
of a number of immunocytochemical panels on pleural fluid cell
blocks or, even better, on pleural biopsy specimens. We found
that high pleural fluid concentrations of 2 classical tumor
markers (i.e., CA15-3 and CA19-9) simultaneously, or alter-
natively an elevated CA19-9 along with low kallikrein-12
concentrations, pointed to a metastatic lung adenocarcinoma
rather than mesothelioma, with 65% sensitivity and 100%
specificity. In a recent meta-analysis of 49 studies, pleural fluid
CA15-3 and CA19-9 exhibited 50.7% and 37.6% pooled sen-
sitivities, respectively, and 98% specificities for diagnosing
malignant effusions.16 Moreover, fluid concentrations may be
significantly different among various tumor types. In this sense,
Wang et al measured the pleural fluid levels of 5 tumor markers,
including CA15-3 and CA19-9, in 251 patients with different
tumors. Significantly higher levels of CA15-3 (138.6 U/mL vs
21.3 U/mL) and CA19-9 (516.6 U/mL vs 181.5 U/mL) were
found in 128 lung adenocarcinoma cases than in 18 mesothe-
liomas.17 Kallikreins are a subgroup of serine proteases which
have been implicated in carcinogenesis. Tissue expression of
kallikreins has been demonstrated in pleural mesothelioma,18
yet explanations for their levels and significance in malignant
pleural fluids is lacking. The observation that soluble mesothe-
lin, the reference biomarker of mesothelioma,19 was not found
to be differentially expressed in mesotheliomas when compared
to lung adenocarcinomas may be explained by the use of a
different platform assay and the fact that a quarter of advanced
lung adenocarcinomas express high levels of mesothelin.20
Regarding the last issue, namely the differentiation
between lymphomatous and tuberculous effusions, cathepsin-
B alone, which promised to be a useful marker in the derivation
sample, failed to confirm these expectations in the validation
sample. It is probable that its combination with VACM-1, the
second most powerful differentially expressed protein in the
random forest analysis, would have increased discriminating
capacity. It is certain that combining cathepsin-B with a simple
clinical variable such as age did greatly enhance lymphoma-TB
separation. This may have been because pleural TB typically
affects younger patients as compared to lymphoma-associated
effusions.1,2,21
During the last decade, the identification of novel bio-
marker candidate proteins of malignant effusions has been
attempted using proteomic analysis. However, most studies
lack adequate sample sizes, are heterogeneous in the compari-
son groups and the proteomic technologies applied, and gener-
ally do not validate their findings.22 The choice of an
appropriate proteomic methodology depends on many factors,
























Malignant (G1) vs TB (G2)

Score: 0–4 0 13













Lung adenocarcinoma (G1) vs mesothelioma (G2)y















Lymphoma (G1) vs TB (G2)




























Protein biomarkers integrated into the scoring system were: metalloproteinase-9 <15.5 ng/mL (3 points), chondroitin sulfate >1.25 ng/mL
(3 points), cathepsin-B <0.42 ng/mL (2 points), and C-reactive protein <12.5 mg/L (1 point).
yProtein biomarkers integrated into the scoring system were: CA19–9 13.3 U/mL (3 points), kallikrein-12 <55 ng/mL (2 points), and CA15–3
>110 U/mL (1 point).
zScore A includes a pleural fluid cathepsin-B level <0.31 ng/mL (1 point).
§ Score B combines a pleural fluid cathepsin-B level <0.31 ng/mL (1 point) with an age 50 years (1 point).AUC¼ area under the curve,
CI¼ confidence interval, G1¼ group 1, G2¼ group 2, LR¼ likelihood ratio, TB¼ tuberculosis.
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including the availability of resources and the number of
samples to be processed. Rather than exploring putative
biomarkers through complex or research-limited proteomic
methodologies in a blinded strategy (i.e., the proteome to be
investigated is not known),23,24 we made use of a biochip
array which allowed us to determine multiple prespecified
protein biomarkers (guided strategy) from a single sample.
We selected commercially available technologies for both the
biomarker chip and protein validation with the aim of increas-
ing the reproducibility and clinical applicability of
our research.
Several limitations of the present study should be
addressed. First, a relatively small number of pleural fluid
samples were tested, particularly from the lymphomatous etiol-
ogy. In fact, we could not firmly verify any set of potential
biomarkers for lymphoma-TB separation, unless used in com-
bination with patient’s age. Second, causes of benign effusions
other than TB were not explored. Therefore, the claimed
biomarkers’ accuracy may not be valid for separating malignant
and non-TB effusions, yet TB is generally the most challenging
differential diagnosis. Lastly, the reported biomarkers need to
be explored and validated in new large independent populations
with the techniques used in the verification stage, and also in a
subgroup of cancer patients with falsely negative or misleading
pleural fluid cytology.
CONCLUSIONS
Our study demonstrated the diagnostic power of a new
panel of biomarkers for the workup of pleural effusions,
specifically for malignant-TB and lung adenocarcinoma-
mesothelioma differentiations. Moreover, single fluid proteins
in combination with clinical parameters such as age may help to
further differentiate lymphomatous and TB effusions. Even
though these panels showed maximal specificity, they are not
intended to replace standardized diagnostic procedures such as
pleural fluid cytology or biopsy for labeling malignant effu-
sions. Rather, they may provide additional information when
deciding whether or not to perform invasive procedures.
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